Persimmune

PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor signature. Just as no two people are alike, no two cancers are exactly alike; because of this, the same immunotherapy treatment that works for one patient may not work well in another. To address this treatment disparity, PersImmune's proprietary protocol, Personal Adoptive Cellular Therapy for Neoantigens (PACTN) identifies the DNA alterations present in the cancer cells of each patient and generates enriched, tested, highly-specific T-cells that effectively kill the patient’s tumor cells. These are the patient's own cells, and are not edited or genetically engineered which means patients will experience far less side effects than from chemotherapy or other methods of immunotherapy. Personalized adoptive cellular therapy has the potential to transform the field of cancer treatment by providing safe, highly-tolerable, effective immunotherapy to cancer patients. Personal immunotherapy - because no two patients are exactly alike. PersImmune is currently accepting patients for the Phase 1 clinical trial of its Personalized Adoptive Cell Transfer technology targeting Neoantigens (PACTN). The trial provides a therapy for early and late stage patients of myelodysplastic syndrome (MDS).